HCPLive
@hcplivenews.bsky.social
Everything you need to enhance your approach to improving patient care.
New phase 3 data show adjunctive lumateperone 42 mg significantly improves #MDD symptoms by day 43, reinforcing its 2025 FDA approval. Read more: www.hcplive.com/view...
December 9, 2025 at 2:00 AM
New phase 3 data show adjunctive lumateperone 42 mg significantly improves #MDD symptoms by day 43, reinforcing its 2025 FDA approval. Read more: www.hcplive.com/view...
Had a hectic November? Catch up on the biggest news in endocrinology with our HCPLive Month in Review, and follow @hcplive for the most impactful news in medicine!
www.hcplive.com/view...
www.hcplive.com/view...
December 7, 2025 at 5:00 PM
Had a hectic November? Catch up on the biggest news in endocrinology with our HCPLive Month in Review, and follow @hcplive for the most impactful news in medicine!
www.hcplive.com/view...
www.hcplive.com/view...
Catch up on any cardiology news you may have missed last month with our HCPLive Cardiology Month in Review!
Read now: www.hcplive.com/view...
Read now: www.hcplive.com/view...
December 6, 2025 at 10:00 PM
Catch up on any cardiology news you may have missed last month with our HCPLive Cardiology Month in Review!
Read now: www.hcplive.com/view...
Read now: www.hcplive.com/view...
On the morning of December 1, the FDA announced acceptance of the supplemental NDA for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide treatment to patients with CHF and CKD in under 10 seconds.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
December 2, 2025 at 3:00 PM
On the morning of December 1, the FDA announced acceptance of the supplemental NDA for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide treatment to patients with CHF and CKD in under 10 seconds.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
New research is shedding light on state- and local-level geographic disparities in the availability of gastroenterologist care, highlighting limited access to care in rural areas and areas with low household incomes relative to urban areas.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
December 2, 2025 at 2:00 AM
New research is shedding light on state- and local-level geographic disparities in the availability of gastroenterologist care, highlighting limited access to care in rural areas and areas with low household incomes relative to urban areas.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
Philip Mease, MD, Clinical Professor @UWMedicine and Director of Rheumatology Research at the Swedish Medical Center, discusses the recent attention to cardiometabolic outcomes in people with rheumatologic diseases. Watch now: www.hcplive.com/view...
November 27, 2025 at 4:00 PM
Philip Mease, MD, Clinical Professor @UWMedicine and Director of Rheumatology Research at the Swedish Medical Center, discusses the recent attention to cardiometabolic outcomes in people with rheumatologic diseases. Watch now: www.hcplive.com/view...
Novo Nordisk's amycretin has demonstrated superior weight loss versus placebo in patients with inadequately controlled type 2 diabetes. The company plans to initiate phase 3 trials in 2026.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
November 26, 2025 at 3:00 PM
Novo Nordisk's amycretin has demonstrated superior weight loss versus placebo in patients with inadequately controlled type 2 diabetes. The company plans to initiate phase 3 trials in 2026.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
Otsuka has submitted an NDA to the #FDA for centanafadine, a first-in-class NDSRI for #ADHD in patients aged 4–55 years. Across 4 phase 3 trials, the once-daily therapy showed significant improvements vs placebo. www.hcplive.com/view...
November 26, 2025 at 2:00 AM
Otsuka has submitted an NDA to the #FDA for centanafadine, a first-in-class NDSRI for #ADHD in patients aged 4–55 years. Across 4 phase 3 trials, the once-daily therapy showed significant improvements vs placebo. www.hcplive.com/view...
Kassandra Holzem, MD, of @MedicalCollege, sat down in an interview with HCPLive at the #SDPAFall2025.🎥
In her on-camera discussion, Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
🔗View: www.hcplive.com/view/difficu...
In her on-camera discussion, Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
🔗View: www.hcplive.com/view/difficu...
November 25, 2025 at 10:05 PM
Kassandra Holzem, MD, of @MedicalCollege, sat down in an interview with HCPLive at the #SDPAFall2025.🎥
In her on-camera discussion, Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
🔗View: www.hcplive.com/view/difficu...
In her on-camera discussion, Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
🔗View: www.hcplive.com/view/difficu...
The OCEANIC-STROKE trial has successfully demonstrated asundexian's capacity to lower ischemic stroke risk - without increasing major bleeding rate - in patients with after an acute non-cardioembolic ischemic stroke.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
November 25, 2025 at 3:00 PM
The OCEANIC-STROKE trial has successfully demonstrated asundexian's capacity to lower ischemic stroke risk - without increasing major bleeding rate - in patients with after an acute non-cardioembolic ischemic stroke.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
ICYMI: New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup with chronic hand #eczema.💡
🌟Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
🔗hcplive.com/view/sub...
🌟Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
🔗hcplive.com/view/sub...
November 23, 2025 at 2:00 AM
ICYMI: New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup with chronic hand #eczema.💡
🌟Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
🔗hcplive.com/view/sub...
🌟Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
🔗hcplive.com/view/sub...
ICYMI: The American Gastroenterological Association released a clinical practice guideline on the pharmacologic management of Crohn’s disease intended to support a comprehensive, patient-centered, evidence-based approach.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
November 23, 2025 at 12:00 AM
ICYMI: The American Gastroenterological Association released a clinical practice guideline on the pharmacologic management of Crohn’s disease intended to support a comprehensive, patient-centered, evidence-based approach.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
During #AHA2025, we spoke with Julia Grapsa, MD, PhD, to address disparities in aortic stenosis care between male and female patients. Read about how clinicians and investigators alike can improve care quality for women: www.hcplive.com/view...
November 22, 2025 at 3:00 PM
During #AHA2025, we spoke with Julia Grapsa, MD, PhD, to address disparities in aortic stenosis care between male and female patients. Read about how clinicians and investigators alike can improve care quality for women: www.hcplive.com/view...
Ixekizumab (IXE) may deliver more durable high-level skin clearance among patients living with #psoriasis than several other commonly used biologic drugs, new-real world findings suggest.💡
🔗View more on these findings: www.hcplive.com/view...
🔗View more on these findings: www.hcplive.com/view...
November 22, 2025 at 4:00 AM
Ixekizumab (IXE) may deliver more durable high-level skin clearance among patients living with #psoriasis than several other commonly used biologic drugs, new-real world findings suggest.💡
🔗View more on these findings: www.hcplive.com/view...
🔗View more on these findings: www.hcplive.com/view...
A phase 2b trial presented as a late breaker at #ACAAI2025 demonstrates the effectiveness of rezpegaldesleukin, an IL-2 receptor pathway agonist, for the treatment of atopic dermatitis and asthma. Learn more: www.hcplive.com/view...
November 22, 2025 at 2:00 AM
A phase 2b trial presented as a late breaker at #ACAAI2025 demonstrates the effectiveness of rezpegaldesleukin, an IL-2 receptor pathway agonist, for the treatment of atopic dermatitis and asthma. Learn more: www.hcplive.com/view...
In the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the significant price drop for Wegovy and Ozempic. These life-changing drugs are now more accessible than ever.
Watch now: www.hcplive.com/view/diabete...
Watch now: www.hcplive.com/view/diabete...
November 21, 2025 at 9:44 PM
In the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the significant price drop for Wegovy and Ozempic. These life-changing drugs are now more accessible than ever.
Watch now: www.hcplive.com/view/diabete...
Watch now: www.hcplive.com/view/diabete...
New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup of chronic hand eczema patients. Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
www.hcplive.com/view...
www.hcplive.com/view...
November 21, 2025 at 4:00 AM
New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup of chronic hand eczema patients. Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look.
www.hcplive.com/view...
www.hcplive.com/view...
Donidalorsen continues to show durable, long-term efficacy for #HAE across OASISplus extension and switch data. Check out interview with Daniel Manning, MD, here: www.hcplive.com/view... #ACAAI2025
November 21, 2025 at 2:00 AM
Donidalorsen continues to show durable, long-term efficacy for #HAE across OASISplus extension and switch data. Check out interview with Daniel Manning, MD, here: www.hcplive.com/view... #ACAAI2025
New from #AHA2025: We met with Martha Gulati, MD, to discuss the difficulties faced by heart failure patients in understanding and adhering to a significantly burdensome therapy structure.
Read our Q&A with Dr. Gulati now: www.hcplive.com/view...
Read our Q&A with Dr. Gulati now: www.hcplive.com/view...
November 20, 2025 at 3:00 PM
New from #AHA2025: We met with Martha Gulati, MD, to discuss the difficulties faced by heart failure patients in understanding and adhering to a significantly burdensome therapy structure.
Read our Q&A with Dr. Gulati now: www.hcplive.com/view...
Read our Q&A with Dr. Gulati now: www.hcplive.com/view...
Could a controlled metabolic accelerator reshape the future of MASH care?
In the following Q&S, Mazen Noureddin, MD, MHSc, breaks down new phase 2 data supporting HU6’s use in MASH: www.hcplive.com/view...
In the following Q&S, Mazen Noureddin, MD, MHSc, breaks down new phase 2 data supporting HU6’s use in MASH: www.hcplive.com/view...
November 20, 2025 at 11:00 AM
Could a controlled metabolic accelerator reshape the future of MASH care?
In the following Q&S, Mazen Noureddin, MD, MHSc, breaks down new phase 2 data supporting HU6’s use in MASH: www.hcplive.com/view...
In the following Q&S, Mazen Noureddin, MD, MHSc, breaks down new phase 2 data supporting HU6’s use in MASH: www.hcplive.com/view...
Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗 www.hcplive.com/view...
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗 www.hcplive.com/view...
November 20, 2025 at 4:00 AM
Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗 www.hcplive.com/view...
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗 www.hcplive.com/view...
A phase 2 study, presented as a late breaker at #ACAAI2025, showed povorcitinib improves itch and hives in 3 days among patients with #CSU. Check out this Q&A with Jonathan A. Bernstein, MD @uofcincy: www.hcplive.com/view...)
November 20, 2025 at 2:00 AM
A phase 2 study, presented as a late breaker at #ACAAI2025, showed povorcitinib improves itch and hives in 3 days among patients with #CSU. Check out this Q&A with Jonathan A. Bernstein, MD @uofcincy: www.hcplive.com/view...)
New data from the phase 3b ADmirable trial show lebrikizumab effectively treats severe atopic dermatitis in patients with skin of color. Vinay Mehta, MD, breaks down what clinicians need to know at #ACAAI2025: www.hcplive.com/view/lebriki...
November 18, 2025 at 10:13 PM
New data from the phase 3b ADmirable trial show lebrikizumab effectively treats severe atopic dermatitis in patients with skin of color. Vinay Mehta, MD, breaks down what clinicians need to know at #ACAAI2025: www.hcplive.com/view/lebriki...
Our top trial recaps from #ACAAI2025 are live.
From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care.
Read the full coverage here: www.hcplive.com/view...
From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care.
Read the full coverage here: www.hcplive.com/view...
November 18, 2025 at 4:00 AM
Our top trial recaps from #ACAAI2025 are live.
From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care.
Read the full coverage here: www.hcplive.com/view...
From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care.
Read the full coverage here: www.hcplive.com/view...
At #ACAAI2025, Gary Gross, MD, outlined the 2025 coding updates allergists need to know to prevent denials and prepare for 2026. He discusses the new ICD-10 food allergy codes and documentation tips.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
November 18, 2025 at 2:00 AM
At #ACAAI2025, Gary Gross, MD, outlined the 2025 coding updates allergists need to know to prevent denials and prepare for 2026. He discusses the new ICD-10 food allergy codes and documentation tips.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...